Carasent AB (SE:CARA)
:CARA
Want to see SE:CARA full AI Analyst Report?
Top Page
Carasent AB
(CARA)
Select Model
Select Model
Rating:61Neutral
Price Target:
kr25.00
▼(-13.79% Downside)
Action:ReiteratedDate:04/14/26
The score is driven mainly by solid underlying business momentum (strong revenue growth and high gross margins) and a low-leverage balance sheet, offset by inconsistent profitability/cash flow and a premium valuation (high P/E). Technicals are mixed, with better short-term trend than long-term.
Positive Factors
Revenue Growth
Sustained very strong top-line growth (TTM ~200%) signals expanding adoption of the company's healthcare software and successful go-to-market execution. Over a 2–6 month horizon this growth supports scale economics, recurring revenue visibility, and provides room to invest in product and sales to deepen market penetration.
Negative Factors
Volatile Profitability
Wide swings in operating performance—losses in 2023–2024, profit in 2025, then renewed pressure in the TTM—indicate the company has not yet established durable operating margins. This variability raises execution risk and complicates forecasting, making sustained conversion of high gross profit into net earnings uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained very strong top-line growth (TTM ~200%) signals expanding adoption of the company's healthcare software and successful go-to-market execution. Over a 2–6 month horizon this growth supports scale economics, recurring revenue visibility, and provides room to invest in product and sales to deepen market penetration.
Read all positive factors
Carasent AB (CARA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.64B
Dividend YieldN/A
Average Volume (3M)175.33K
Price to Earnings (P/E)143.4
Beta (1Y)<0.01
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees196
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.04
Shares Outstanding72,324,780
10 Day Avg. Volume229,351
30 Day Avg. Volume175,329
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)2.36
Price to Sales (P/S)5.54
P/FCF Ratio-4.00K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.51
Revenue Forecast (FY)kr377.50M
Carasent AB Business Overview & Revenue Model
Company Description
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webdoc X, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. I...
How the Company Makes Money
Carasent primarily makes money by selling access to its healthcare software products and related services. Specific public breakdowns of revenue streams (e.g., the split between recurring subscriptions/licenses, implementation fees, support/mainte...
Carasent AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
84
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 266.85M | 343.82M | 275.26M | 243.98M | 195.26M | 137.13M |
| Gross Profit | 223.34M | 289.00M | 232.71M | 197.77M | 161.42M | 112.90M |
| EBITDA | 54.08M | 73.34M | 17.52M | 2.91M | 58.81M | 17.91M |
| Net Income | 26.49M | 34.67M | -42.26M | -46.45M | 31.17M | -148.00K |
Balance Sheet | ||||||
| Total Assets | 921.88M | 941.01M | 1.07B | 1.09B | 1.37B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 130.03M | 139.48M | 262.02M | 373.88M | 694.83M | 882.77M |
| Total Debt | 28.91M | 31.94M | 41.20M | 50.17M | 38.88M | 16.34M |
| Total Liabilities | 141.85M | 133.00M | 179.42M | 138.24M | 144.30M | 129.54M |
| Stockholders Equity | 780.03M | 808.00M | 892.87M | 955.41M | 1.23B | 1.17B |
Cash Flow | ||||||
| Free Cash Flow | 46.33M | -476.00K | -5.15M | -73.67M | -57.95M | -5.75M |
| Operating Cash Flow | 76.32M | 40.44M | 37.73M | -4.47M | 33.61M | 32.48M |
| Investing Cash Flow | -27.49M | -35.98M | -120.07M | -55.53M | -209.50M | -125.12M |
| Financing Cash Flow | -88.48M | -122.22M | -16.38M | -263.28M | -10.20M | 756.56M |
Carasent AB Technical Analysis
Neutral
29.00
Price Trends
23.37
Positive
25.09
Negative
26.39
Negative
Market Momentum
-0.04
Negative
51.08
Neutral
38.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARA, the sentiment is Neutral. The current price of 29 is above the 20-day moving average (MA) of 23.12, above the 50-day MA of 23.37, and above the 200-day MA of 26.39, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 51.08 is Neutral, neither overbought nor oversold. The STOCH value of 38.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CARA.
Carasent AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:CARA
Carasent AB
23.90
-0.96
-3.88%
DE:7JK
EQL Pharma AB
4.53
-2.45
-35.10%
DE:6Y4
Vicore Pharma Holding AB
0.86
0.12
15.92%
DE:47H
Humana AB
4.37
0.91
26.41%
DE:6XP
Xspray Pharma AB
2.33
-0.70
-23.15%
DE:7D2A
Sedana Medical AB
0.88
0.02
2.80%
Carasent AB Corporate Events
Carasent Sets 14 April Date for Q1 2026 Results and Webcast
Apr 8, 2026
Carasent AB will publish its interim report for the first quarter of 2026 on 14 April at 07:00 CET, as the healthtech group continues its regular financial reporting to investors and other stakeholders. The timing of the release positions the comp...
Carasent Calls AGM with Proposals on Incentive Scheme and Capital Measures
Mar 19, 2026
Carasent AB has called its Annual General Meeting for 20 April 2026 in Stockholm, inviting shareholders registered with Euroclear Sweden and those holding shares via Euronext Securities Oslo to participate subject to specific registration and noti...
Carasent Boosts Growth and Swings to Profit in 2025
Feb 12, 2026
Carasent AB reported strong full-year 2025 results, with net sales rising 25% to SEK 343.8 million, driven by 14% organic growth and contributions from acquisitions. The company significantly improved profitability, turning EBITDA to SEK 73.3 mill...
Carasent to Present Q4 2025 Interim Results on 12 February
Feb 9, 2026
Carasent AB, a Swedish healthcare technology company providing digital solutions to healthcare providers, will publish its interim report for the fourth quarter of 2025 on 12 February 2026 at 07:00 CET. The business focuses on software and digital...
Carasent Nomination Committee Proposes Unchanged Board Line-Up for 2026 AGM
Feb 6, 2026
Carasent AB’s nomination committee has presented its proposal for the composition of the board of directors ahead of the company’s 2026 annual general meeting, recommending that the board remain at five members. The committee proposes ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.